English

Intercept Pharmaceuticals, Inc.

EDGAR

ICPT Quarterly report (10-Q) · filed 2023-11-06

156 filing records in this dataset, filed from 2012-09-04 to 2023-11-06. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

88.8 million Unit_Standard_USD_Kf6sTVqbV0y46p0PM8mi5w

2023 Q3 · Unit_Standard_USD_Kf6sTVqbV0y46p0PM8mi5w

Exact inputs and evidence

Revenue: 88789000 Unit_Standard_USD_Kf6sTVqbV0y46p0PM8mi5w Source

Operating margin

-5.2%

2023 Q3 · %

Exact inputs and evidence

Operating Income: -4619000 Unit_Standard_USD_Kf6sTVqbV0y46p0PM8mi5w Source
Revenue: 88789000 Unit_Standard_USD_Kf6sTVqbV0y46p0PM8mi5w Source

Cash and cash equivalents: 103 million Unit_Standard_USD_Kf6sTVqbV0y46p0PM8mi5w 2023-09-30 Source
Exact value

102736000 Unit_Standard_USD_Kf6sTVqbV0y46p0PM8mi5w
Long-term debt including current maturities: 224 million Unit_Standard_USD_etiRA92dikiDsPINGf4fSA 2023-06-30 Source
Exact value

223603000 Unit_Standard_USD_etiRA92dikiDsPINGf4fSA
Shares outstanding: 41.8 million Unit_Standard_shares_4sM9n_WwQUS11D-v8oUMOA 2023-09-30 Source
Exact value

41811686 Unit_Standard_shares_4sM9n_WwQUS11D-v8oUMOA

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-11-06.

Financial data available through: 2022-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2022-12-31
Operating income: 3 of 11 periods available· newest 2022-12-31
Net income: 3 of 11 periods available· newest 2022-12-31
Operating cash flow: 3 of 11 periods available· newest 2022-12-31
Capital expenditure: 3 of 11 periods available· newest 2022-12-31
Total assets: Multiple units; comparison withheld· newest 2022-12-31
Total liabilities: Multiple units; comparison withheld· newest 2022-12-31
Current assets: Multiple units; comparison withheld· newest 2022-12-31
Current liabilities: Multiple units; comparison withheld· newest 2022-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2022-12-31
Long-term debt including current maturities: Multiple units; comparison withheld· newest 2022-12-31
Shares outstanding: Multiple units; comparison withheld· newest 2022-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+9.6%

Prior period

Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 260.75 million

2021-01-01 – 2021-12-31
Current period

Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 285.71 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

285710000 − 260750000 = 24960000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew

260750000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
285710000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Intercept Pharmaceuticals, Inc. · 2022-12-31 Intercept Pharmaceuticals, Inc. (edgar:1270073) Year-over-year change in Revenue: 24960000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Concept: fundies:Revenue Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:01:22Z Snapshot: fd4dd99f29f0f446349663eda87c2b871aba7df57b87c680cac5f6c75b287541 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1270073?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 285710000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#3653656 Filing: 000155837023002693 Input fundies:Revenue: 260750000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#3701769 Filing: 000155837023002693
The citation records this snapshot. The page link may show a newer release later.
Net income
+Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 313.24 million

Prior period

−Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 91.43 million

2021-01-01 – 2021-12-31
Current period

Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 221.82 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

221816000 − -91426000 = 313242000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew

-91426000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
221816000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Intercept Pharmaceuticals, Inc. · 2022-12-31 Intercept Pharmaceuticals, Inc. (edgar:1270073) Year-over-year change in Net income: 313242000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:01:22Z Snapshot: fd4dd99f29f0f446349663eda87c2b871aba7df57b87c680cac5f6c75b287541 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1270073?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 221816000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#3673530 Filing: 000155837023002693 Input fundies:NetIncome: -91426000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#3721633 Filing: 000155837023002693
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 14.29 million

Prior period

−Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 41.07 million

2021-01-01 – 2021-12-31
Current period

−Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 26.78 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-26780000 − -41066000 = 14286000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew

-41066000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-26780000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Intercept Pharmaceuticals, Inc. · 2022-12-31 Intercept Pharmaceuticals, Inc. (edgar:1270073) Year-over-year change in Operating cash flow: 14286000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:01:22Z Snapshot: fd4dd99f29f0f446349663eda87c2b871aba7df57b87c680cac5f6c75b287541 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1270073?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -26780000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#2106096 Filing: 000155837023002693 Input fundies:OperatingCashFlow: -41066000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#2107205 Filing: 000155837023002693
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+43.1%

Prior period

Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 397,000

2021-01-01 – 2021-12-31
Current period

Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 568,000

2022-01-01 – 2022-12-31

Exact inputs and evidence

568000 − 397000 = 171000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew

397000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
568000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Intercept Pharmaceuticals, Inc. · 2022-12-31 Intercept Pharmaceuticals, Inc. (edgar:1270073) Year-over-year change in Capital expenditure: 171000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:01:22Z Snapshot: fd4dd99f29f0f446349663eda87c2b871aba7df57b87c680cac5f6c75b287541 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1270073?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 568000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#2118613 Filing: 000155837023002693 Input fundies:CapitalExpenditure: 397000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#2119710 Filing: 000155837023002693
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 285.71 million 100% of revenue
Cost of revenue Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 984,000 0.3% of revenue
Operating expenses Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 352.94 million 124% of revenue
Operating income −Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 68.22 million −24% of revenue
Tax, interest and other Derived −Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 290.03 million −102% of revenue
Net income Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 221.82 million 78% of revenue

Cash

Operating cash flow −Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 26.78 million −9.4% of revenue
Capital expenditure Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 568,000 0.2% of revenue
Free cash flow Derived −Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 27.35 million −9.6% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Operating loss: operating costs were 198% of revenue.
2021 Operating loss: operating costs were 139% of revenue.
2022 Operating loss: operating costs were 124% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	233970000	463697000 Derived	-229727000	45153000 Derived	-274880000	-175755000 Derived	Source 2020-01-01 – 2020-12-31: 233970000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Revenue Open source 2020-01-01 – 2020-12-31: -229727000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -274880000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Net Income Open source 2020-01-01 – 2020-12-31: -171864000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 3891000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	260750000	361156000 Derived	-100406000	-8980000 Derived	-91426000	-41463000 Derived	Source 2021-01-01 – 2021-12-31: 260750000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Revenue Open source 2021-01-01 – 2021-12-31: -100406000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -91426000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Net Income Open source 2021-01-01 – 2021-12-31: -41066000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 397000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	285710000	353926000 Derived	-68216000	-290032000 Derived	221816000	-27348000 Derived	Source 2022-01-01 – 2022-12-31: 285710000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Revenue Open source 2022-01-01 – 2022-12-31: -68216000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Operating Income Open source 2022-01-01 – 2022-12-31: 221816000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Net Income Open source 2022-01-01 – 2022-12-31: -26780000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 568000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Capital Expenditure Open source

Amounts are exact, in Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 285.7M 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew)	Source evidence
20202020-12-31	Revenue	233970000	Revenue: 233970000 Open source
20212021-12-31	Revenue	260750000	Revenue: 260750000 Open source
20222022-12-31	Revenue	285710000	Revenue: 285710000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

9.6% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 233970000 Open source
20212021-12-31	Year over year	11.4%	Revenue: 260750000 Open source Revenue: 233970000 Open source
20222022-12-31	Year over year	9.6%	Revenue: 285710000 Open source Revenue: 260750000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -23.9% 2022

Net margin 77.6% 2022

Free cash flow margin -9.6% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	-98.2%	Operating Income: -229727000 Open source Revenue: 233970000 Open source
20212021-12-31	Operating margin	-38.5%	Operating Income: -100406000 Open source Revenue: 260750000 Open source
20222022-12-31	Operating margin	-23.9%	Operating Income: -68216000 Open source Revenue: 285710000 Open source
20202020-12-31	Net margin	-117.5%	Net Income: -274880000 Open source Revenue: 233970000 Open source
20212021-12-31	Net margin	-35.1%	Net Income: -91426000 Open source Revenue: 260750000 Open source
20222022-12-31	Net margin	77.6%	Net Income: 221816000 Open source Revenue: 285710000 Open source
20202020-12-31	Free cash flow margin	-75.1%	Revenue: 233970000 Open source Operating Cash Flow: -171864000 Open source Capital Expenditure: 3891000 Open source
20212021-12-31	Free cash flow margin	-15.9%	Revenue: 260750000 Open source Operating Cash Flow: -41066000 Open source Capital Expenditure: 397000 Open source
20222022-12-31	Free cash flow margin	-9.6%	Revenue: 285710000 Open source Operating Cash Flow: -26780000 Open source Capital Expenditure: 568000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew -26.8M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew)	Source evidence
20202020-12-31	Operating cash flow	-171864000	Operating Cash Flow: -171864000 Open source
20212021-12-31	Operating cash flow	-41066000	Operating Cash Flow: -41066000 Open source
20222022-12-31	Operating cash flow	-26780000	Operating Cash Flow: -26780000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew -27.3M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew)	Source evidence
20202020-12-31	Free cash flow	-175755000	Operating Cash Flow: -171864000 Open source Capital Expenditure: 3891000 Open source
20212021-12-31	Free cash flow	-41463000	Operating Cash Flow: -41066000 Open source Capital Expenditure: 397000 Open source
20222022-12-31	Free cash flow	-27348000	Operating Cash Flow: -26780000 Open source Capital Expenditure: 568000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2020-12-31	Liabilities / assets	Not reported	No source recorded
2021-12-31	Liabilities / assets	Not reported	No source recorded
2022-12-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2020-12-31	Current assets / current liabilities	Not reported	No source recorded
2021-12-31	Current assets / current liabilities	Not reported	No source recorded
2022-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	−Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 274.88 million Exact value Exact value: -274880000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 2020-01-01 – 2020-12-31: -274880000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Net Income Open source Share or cite Citation for Net Income · Intercept Pharmaceuticals, Inc. · 2020-12-31 Intercept Pharmaceuticals, Inc. (edgar:1270073) Net Income: -274880000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:01:22Z Snapshot: fd4dd99f29f0f446349663eda87c2b871aba7df57b87c680cac5f6c75b287541 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1270073/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew&dimensions= Input fundies:NetIncome: -274880000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#1763180 Filing: 000155837023002693 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 171.86 million Exact value Exact value: -171864000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 2020-01-01 – 2020-12-31: -171864000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intercept Pharmaceuticals, Inc. · 2020-12-31 Intercept Pharmaceuticals, Inc. (edgar:1270073) Operating Cash Flow: -171864000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:01:22Z Snapshot: fd4dd99f29f0f446349663eda87c2b871aba7df57b87c680cac5f6c75b287541 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1270073/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew&dimensions= Input fundies:OperatingCashFlow: -171864000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#2108314 Filing: 000155837023002693 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 3.89 million Exact value Exact value: 3891000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 2020-01-01 – 2020-12-31: 3891000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intercept Pharmaceuticals, Inc. · 2020-12-31 Intercept Pharmaceuticals, Inc. (edgar:1270073) Capital Expenditure: 3891000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:01:22Z Snapshot: fd4dd99f29f0f446349663eda87c2b871aba7df57b87c680cac5f6c75b287541 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1270073/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew&dimensions= Input fundies:CapitalExpenditure: 3891000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#2120807 Filing: 000155837023002693 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 175.76 million Calculation and evidence -171864000 − 3891000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Exact free cash flow: -175755000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 2020-01-01 – 2020-12-31: -171864000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 3891000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intercept Pharmaceuticals, Inc. · 2020-12-31 Intercept Pharmaceuticals, Inc. (edgar:1270073) Free cash flow: -175755000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:01:22Z Snapshot: fd4dd99f29f0f446349663eda87c2b871aba7df57b87c680cac5f6c75b287541 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1270073?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -171864000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#2108314 Filing: 000155837023002693 Input fundies:CapitalExpenditure: 3891000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#2120807 Filing: 000155837023002693 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 91.43 million Exact value Exact value: -91426000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 2021-01-01 – 2021-12-31: -91426000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Net Income Open source Share or cite Citation for Net Income · Intercept Pharmaceuticals, Inc. · 2021-12-31 Intercept Pharmaceuticals, Inc. (edgar:1270073) Net Income: -91426000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:01:22Z Snapshot: fd4dd99f29f0f446349663eda87c2b871aba7df57b87c680cac5f6c75b287541 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1270073/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew&dimensions= Input fundies:NetIncome: -91426000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#3721633 Filing: 000155837023002693 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 41.07 million Exact value Exact value: -41066000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 2021-01-01 – 2021-12-31: -41066000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intercept Pharmaceuticals, Inc. · 2021-12-31 Intercept Pharmaceuticals, Inc. (edgar:1270073) Operating Cash Flow: -41066000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:01:22Z Snapshot: fd4dd99f29f0f446349663eda87c2b871aba7df57b87c680cac5f6c75b287541 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1270073/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew&dimensions= Input fundies:OperatingCashFlow: -41066000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#2107205 Filing: 000155837023002693 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 397,000 Exact value Exact value: 397000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 2021-01-01 – 2021-12-31: 397000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intercept Pharmaceuticals, Inc. · 2021-12-31 Intercept Pharmaceuticals, Inc. (edgar:1270073) Capital Expenditure: 397000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:01:22Z Snapshot: fd4dd99f29f0f446349663eda87c2b871aba7df57b87c680cac5f6c75b287541 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1270073/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew&dimensions= Input fundies:CapitalExpenditure: 397000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#2119710 Filing: 000155837023002693 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 41.46 million Calculation and evidence -41066000 − 397000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Exact free cash flow: -41463000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 2021-01-01 – 2021-12-31: -41066000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 397000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intercept Pharmaceuticals, Inc. · 2021-12-31 Intercept Pharmaceuticals, Inc. (edgar:1270073) Free cash flow: -41463000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:01:22Z Snapshot: fd4dd99f29f0f446349663eda87c2b871aba7df57b87c680cac5f6c75b287541 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1270073?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -41066000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#2107205 Filing: 000155837023002693 Input fundies:CapitalExpenditure: 397000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#2119710 Filing: 000155837023002693 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 221.82 million Exact value Exact value: 221816000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 2022-01-01 – 2022-12-31: 221816000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Net Income Open source Share or cite Citation for Net Income · Intercept Pharmaceuticals, Inc. · 2022-12-31 Intercept Pharmaceuticals, Inc. (edgar:1270073) Net Income: 221816000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:01:22Z Snapshot: fd4dd99f29f0f446349663eda87c2b871aba7df57b87c680cac5f6c75b287541 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1270073/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew&dimensions= Input fundies:NetIncome: 221816000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#3673530 Filing: 000155837023002693 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 26.78 million Exact value Exact value: -26780000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 2022-01-01 – 2022-12-31: -26780000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intercept Pharmaceuticals, Inc. · 2022-12-31 Intercept Pharmaceuticals, Inc. (edgar:1270073) Operating Cash Flow: -26780000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:01:22Z Snapshot: fd4dd99f29f0f446349663eda87c2b871aba7df57b87c680cac5f6c75b287541 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1270073/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew&dimensions= Input fundies:OperatingCashFlow: -26780000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#2106096 Filing: 000155837023002693 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 568,000 Exact value Exact value: 568000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 2022-01-01 – 2022-12-31: 568000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intercept Pharmaceuticals, Inc. · 2022-12-31 Intercept Pharmaceuticals, Inc. (edgar:1270073) Capital Expenditure: 568000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:01:22Z Snapshot: fd4dd99f29f0f446349663eda87c2b871aba7df57b87c680cac5f6c75b287541 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1270073/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew&dimensions= Input fundies:CapitalExpenditure: 568000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#2118613 Filing: 000155837023002693 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 27.35 million Calculation and evidence -26780000 − 568000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Exact free cash flow: -27348000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew 2022-01-01 – 2022-12-31: -26780000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 568000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intercept Pharmaceuticals, Inc. · 2022-12-31 Intercept Pharmaceuticals, Inc. (edgar:1270073) Free cash flow: -27348000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:01:22Z Snapshot: fd4dd99f29f0f446349663eda87c2b871aba7df57b87c680cac5f6c75b287541 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1270073?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -26780000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#2106096 Filing: 000155837023002693 Input fundies:CapitalExpenditure: 568000 Unit_Standard_USD_gToEaP4vT06aEAoKx7B7ew (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1270073/000155837023002693/icpt-20221231x10k.htm#2118613 Filing: 000155837023002693 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

156 filings · 5,218 latest values · 5,218 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001270073, 1270073, ICPT, edgar:1270073, icpt

Also known as INTERCEPT PHARMACEUTICALS INC, INTERCEPT PHARMACEUTICALS, INC., INTERCEPT PHARMACEUTICALS, INC., Intercept Pharmaceuticals, Inc., Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

Latest quarter

Revenue

Operating margin

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation